Tetratherix

Tetratherix Current Assets

The Current Assets of Tetratherix (TTX.AX) as of Oct 27, 2026 is 252,121.00 AUD. In the previous year, Current Assets was 30.73 M AUD — a change of -99.18% (lower).

Current Assets

252,121.00AUD

YoY

-99.18%

Last updated:

Current Assets of Tetratherix is 2026 252,121.00 AUD. Current Assets of Tetratherix was 2025 30.73 M AUD. It decreases by -99.18% lower compared to the previous year.

The Tetratherix Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2023
365,470.00 AUD
Jan 1, 2024
133,150.00 AUD
Jan 1, 2025
30.73 M AUD
Jan 1, 2026
252,121.00 AUD
The Tetratherix Current Assets history
YEARCurrent AssetsYoY
252,121.00AUD-99.18%
30.73 MAUD+22,978.08%
133,150.00AUD-63.57%
365,470.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tetratherix Stock analysis

What does Tetratherix do? Tetratherix Ltd. develops a biostealth fluid matrix for regenerative medicine, creating injectable products that form 3D matrices upon physiological temperature exposure. The company's biomaterial platform uses polymer programming for implantable solutions, with Tegenix and TegenEOS serving as carriers mixed with bone graft materials for dental, oral, and orthopedic applications. TetraDerm products address surgical incision sites to minimize scarring, while Tutelix functions as a spacer to mitigate radiation therapy side effects in prostate cancer. The firm's manufacturing center in Sydney handles cleanroom production of these medical solutions. The company's revenue streams come from selling Tegenix, TegenEOS, TetraDerm, and Tutelix products to healthcare providers, hospitals, and medical device distributors specializing in regenerative medicine. These products target clinical segments including dental procedures, orthopedic surgery, and oncology treatments. Tetratherix's injectable fluid matrix technology differentiates its offerings by enabling tissue integration without causing bodily damage during application, supporting its positioning in the regenerative medicine market. Tegenix and TegenEOS are marketed as complementary solutions for bone graft applications, while TetraDerm focuses on post-surgical scar reduction. Tutelix specifically addresses radiation therapy side effects in prostate cancer patients. The company's manufacturing center in Sydney ensures quality production of these medical products, which are distributed to healthcare professionals across dental, orthopedic, and oncology fields. Tetratherix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tetratherix stock

Current Assets of Tetratherix is 252,121.00 AUD in 2026.

Current Assets of Tetratherix changed from 30.73 M AUD to 252,121.00 AUD, representing a -99.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Tetratherix since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Tetratherix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Tetratherix

All Key Metrics — Tetratherix